<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Riethmüller S</dc:creator>
  <dc:creator>Ferrari-Lacraz S</dc:creator>
  <dc:creator>Müller MK</dc:creator>
  <dc:creator>Raptis DA</dc:creator>
  <dc:creator>Hadaya K</dc:creator>
  <dc:creator>Rüsi B</dc:creator>
  <dc:creator>Laube G</dc:creator>
  <dc:creator>Schneiter G</dc:creator>
  <dc:creator>Fehr T</dc:creator>
  <dc:creator>Villard J</dc:creator>
  <dc:date>2010</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">BACKGROUND
This study evaluated the prognostic impact of pretransplant donor-specific anti-human leukocyte antigen antibodies (DSA) detected by single-antigen beads and compared the three generations of crossmatch (XM) tests in kidney transplantation.


METHODS
Thirty-seven T-cell complement-dependent cytotoxicity crossmatch (CXM) negative living donor kidney recipients with a retrospectively positive antihuman leukocyte antigen antibody screening assay were included. A single-antigen bead test, a flow cytometry XM, and a Luminex XM (LXM) were retrospectively performed, and the results were correlated with the occurrence of antibody-mediated rejections (AMRs) and graft function.


RESULTS
We found that (1) pretransplant DSA against class I (DSA-I), but not against class II, are predictive for AMR, resulting in a sensitivity of 75% and a specificity of 90% at a level of 900 mean fluorescence intensity (MFI); (2) with increasing strength of DSA-I, the sensitivity for AMR is decreasing to 50% and the specificity is increasing to 100% at 5200 MFI; (3) the LXM for class I, but not for class II, provides a higher accuracy than the flow cytometry XM and the B-cell CXM. The specificity of all XMs is increased greatly in combination with DSA-I values more than or equal to 900 MFI.


CONCLUSIONS
In sensitized recipients, the best prediction of AMR and consecutively reduced graft function is delivered by DSA-I alone at high strength or by DSA-I at low strength in combination with the LXM or CXM.</dc:description>
  <dc:identifier>https://sonar.ch/global/documents/244197</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1097/tp.0b013e3181e36e08</dc:relation>
  <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/20658760</dc:relation>
  <dc:source>Transplantation. - 2010</dc:source>
  <dc:subject xmlns:ns1="xml" ns1:lang="en">Adult</dc:subject>
  <dc:subject xmlns:ns2="xml" ns2:lang="en">Female</dc:subject>
  <dc:subject xmlns:ns3="xml" ns3:lang="en">Flow Cytometry</dc:subject>
  <dc:subject xmlns:ns4="xml" ns4:lang="en">Graft Rejection</dc:subject>
  <dc:subject xmlns:ns5="xml" ns5:lang="en">HLA Antigens</dc:subject>
  <dc:subject xmlns:ns6="xml" ns6:lang="en">Histocompatibility Testing</dc:subject>
  <dc:subject xmlns:ns7="xml" ns7:lang="en">Humans</dc:subject>
  <dc:subject xmlns:ns8="xml" ns8:lang="en">Immunosuppression</dc:subject>
  <dc:subject xmlns:ns9="xml" ns9:lang="en">Isoantibodies</dc:subject>
  <dc:subject xmlns:ns10="xml" ns10:lang="en">Kidney Transplantation</dc:subject>
  <dc:subject xmlns:ns11="xml" ns11:lang="en">Living Donors</dc:subject>
  <dc:subject xmlns:ns12="xml" ns12:lang="en">Lymphocytes</dc:subject>
  <dc:subject xmlns:ns13="xml" ns13:lang="en">Male</dc:subject>
  <dc:subject xmlns:ns14="xml" ns14:lang="en">Middle Aged</dc:subject>
  <dc:subject xmlns:ns15="xml" ns15:lang="en">Prognosis</dc:subject>
  <dc:subject xmlns:ns16="xml" ns16:lang="en">ROC Curve</dc:subject>
  <dc:subject xmlns:ns17="xml" ns17:lang="en">Reoperation</dc:subject>
  <dc:subject xmlns:ns18="xml" ns18:lang="en">Retrospective Studies</dc:subject>
  <dc:subject xmlns:ns19="xml" ns19:lang="en">Tissue Donors</dc:subject>
  <dc:title xmlns:ns20="xml" ns20:lang="en">Donor-specific antibody levels and three generations of crossmatches to predict antibody-mediated rejection in kidney transplantation.</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
